Getting the details right: Gene signatures for cancer therapy

Clinical Chemistry

Volumn 56, Issue 9, 2010, Pages 1378-1380

  Master, Stephen R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOINFORMATICS; CANCER THERAPY; DOWN REGULATION; GENE EXPRESSION; HUMAN; MICROARRAY ANALYSIS; SHORT SURVEY;

ANTINEOPLASTIC AGENTS; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; NEOPLASMS; PEER REVIEW; PERIODICALS AS TOPIC; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 77956353475     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.147686     Document Type: Short Survey

References (5)

1. Baggerly KA, Coombes KR. Deriving chemosensitivity from cell lines: forensic bioinformatics and reproducible research in high-throughput biology. Ann Appl Stat 2009;3:1309-34.
2. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294-300. (Pubitemid 44706932)
3. Hsu DS, Balakumaran BS, Acharya CR, Vlahovic V, Walters KS, Garman K, et al. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 2007;25:4350-7. (Pubitemid 350013839)
4. Augustine CK, Yoo JS, Potti A, Yoshimoto Y, Zipfel PA, Friedman HS, et al. Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res 2009;15:502-10.
5. Hutson S. Data handling errors spur debate over clinical trial [News]. Nat Med 2010;16:618.